At TNeuroPharma, we believe in the power of innovative science.
We believe that there’s always another way to look at a problem to find a solution. We believe that in the complex area of neurodegenerative diseases, an earlier definitive diagnosis could be the root for understanding -- and the key to moving forward.
Most importantly, we believe that effective treatments for Alzheimer’s disease and other neurodegenerative disorders are within our reach. And our goal is to assist and support today’s pharmaceutical companies reach the milestone the world has been waiting for when it comes to drug development for Alzheimer’s and other neurodegenerative diseases.
With TNeuroPharma’s technology and patented biomarker kit, pharmaceutical companies can, for the first time, identify patients with confirmed Alzheimer’s disease to study in their clinical trials – two steps ahead of anything that is being used to detect AD so far. By working with confirmed AD patients rather than waiting for a definitive diagnosis upon autopsy, pharmaceutical companies can see if their drug is work in real time -- saving hundreds of millions of dollars and decades of time in the development of effective treatments for Alzheimer’s disease. Most importantly, though, the world can have new hope when it comes to overcoming the many challenges presented by this complex disease.
We are currently partnering with the University of Antwerp and University of Groningen. These universities have a substantial biobank of validated blood samples from Alzheimer's patients as well as controls. The biobank is under the direction of Prof. Peter Paul De Deyn, MD, PhD, a leading researcher who has published 725 papers on dementia and memory disorders, including 253 referencing Alzheimer's specifically. Pilot studies are underway to validate the biomarker in Dr. De Deyn's repository samples.